home / lobbying

lobbying_activities

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

1,156 rows where filing_year = 2018 and issue_code = "PHA" sorted by filing_year descending

✎ View and edit SQL

This data as json, CSV (advanced)

Suggested facets: filing_type, is_termination, received_date (date)

filing_period 4

  • third_quarter 305
  • fourth_quarter 288
  • second_quarter 282
  • first_quarter 281

issue_code 1

  • PHA · 1,156 ✖

filing_year 1

  • 2018 · 1,156 ✖
id filing_uuid filing_type registrant_name registrant_id client_name filing_year ▲ filing_period issue_code specific_issues government_entities income_amount expense_amount is_no_activity is_termination received_date
2101605 HOLLAND & KNIGHT LLP bbc93648-c4b8-4d91-896d-3c6dcb937ff8 Q1 HOLLAND & KNIGHT LLP 18466 THE BIOSIMILARS FORUM 2018 first_quarter PHA Medicare reimbursement issues, FDA regulation of biosimilars; H.R. 1625, Consolidated Appropriations Act of 2018. Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 120000   0 0 2018-04-02T14:15:27.313000-04:00
2101608 HOLLAND & KNIGHT LLP f8f1c435-d277-4277-933e-b420086e1308 Q1 HOLLAND & KNIGHT LLP 18466 PROTECTING ACCESS TO PAIN RELIEF COALITION 2018 first_quarter PHA Advocating for policy to ensure patient access to pain relief; H.R. 664, Stop OD Act of 2017; S.1554, Safer Prescribing of Controlled Substances Act; H.R. 3964, Opioid Addiction Prevention Act of 2017; H.R. 2063, Opioid PACE Act of 2017. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2018-04-02T14:22:30.077000-04:00
2101767 MS. TAMI WAHL 6736cab0-1b17-4797-8ebc-7041c21e7d11 Q1 MS. TAMI WAHL 401104405 ROCK & ASSOCIATES 2018 first_quarter PHA Legislation impacting the operation of pharmacy compounding, and access to compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017. HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2018-04-03T08:17:03.813000-04:00
2102021 AMERICAN COLLEGE OF CLINICAL PHARMACY 881c774b-1fff-4ebc-a9ec-dca34b11e495 Q1 AMERICAN COLLEGE OF CLINICAL PHARMACY 57258 AMERICAN COLLEGE OF CLINICAL PHARMACY 2018 first_quarter PHA Coverage for direct patient care services of qualified pharmacists under Medicare and other public health programs. Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE   144981 0 0 2018-04-04T11:26:16.370000-04:00
2102350 CHATMAN, LLC 95364518-a789-4e03-8d82-eda75c631163 Q1 CHATMAN, LLC 400678024 LIVINGSTON GROUP FOR RUSH UNIVERSITY MEDICAL CENTER 2018 first_quarter PHA Support continuation of Pharmacy 340B program in HRSA. HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2018-04-05T22:28:42.850000-04:00
2102406 PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION 3b892256-655d-4d61-aa8c-0a4181ebec2f Q1 PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION 401103605 PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION 2018 first_quarter PHA Lobbied for OTC Monograph Reform bill, answered questions about opioid manufacturing/packaging, discussed potential solutions to drug shortage situations, and provided general education about the pharma/biopharma contract services sector. HOUSE OF REPRESENTATIVES,SENATE   50000 0 0 2018-04-06T10:18:42.090000-04:00
2102509 RED+BLUE STRATEGIES a31e9579-befa-4e13-8edc-29120d4b4892 Q1 RED+BLUE STRATEGIES 400693064 EXPRESS SCRIPTS INC. 2018 first_quarter PHA H.R. 1625/PL 115-141 - Consolidated Appropriations Act of 2018 - Issues related to access to and affordability of prescription medications and inclusion of tools to fight the opioid epidemic. H.R. 1301/PL 115-124 - Continuing Resolution of 2018 - Issues related to access to and affordability of prescription medications and policies and resources to fight the opioid crisis in the United States. CMS regulations regarding the Part D program and the role of prescription drug plans. S. 637 - Creating Transparency to have Prescription Drug Rebates Unlocked - Issues related to the alleged relationship between rebates and drug prices. S. 771 - A bill to Improve Access to Affordable Prescription Drugs - Issue related to bringing drug pricing down including better policies in the Part D coverage gap, couponing and advancing biosimilars. H.R. 281- National Defense Authorization Act for FY 2018- Issues related to prescription medications for military personnel and their families. H.R. 3447 - Furthering Access to Coordinated Treatment for Seniors (FACTS) Act of 2017 - Working to explain the need for safe and confidential data sharing between Medicare part A, B, and D to ensure better coordination of patient care. Issues related to Direct and Indirect Renumeration policies and their impact on consumers. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2018-04-06T14:05:22.117000-04:00
2102542 RED+BLUE STRATEGIES 40ae77a2-61f3-4e92-889c-c90dad2c92f0 Q1 RED+BLUE STRATEGIES 400693064 PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA) 2018 first_quarter PHA H.R. 1625/PL 115-141 - Consolidated Appropriations Act of 2018 - Issues related to access and affordability of prescription medications and policies to combat the opioid crisis in the United States. H.R. 1301/PL 115-124 - Continuing Resolution of 2018 - Issues related access and affordability of prescription medications in the United States, treatment of biosimilars and generics in public and private insurance and policies to combat the opioid crisis in the United States. CMS Regulations related to the Medicare Part D program and Prescription Drug Plans (PDPs) S. 637 - Creating Transparency to Have Prescription Drug Rebates Unlocked - Issues related to the alleged relationship between rebates and drug prices. S. 771 - A Bill to Improve Access to Affordable Prescription Drugs - Issues related to bringing drug prices down including strengthening policies in the Part D coverage gap, couponing and advancing biosimilars. Education activities for Members and staff related to Direct and Indirect Renumeration(DIR)policies. Education activities related to the cross referencing of certain data related to Medicare Parts A, B and D. Issues related to lowering the price of prescription medications in the United States. HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE,White House Office 60000   0 0 2018-04-06T15:08:50.833000-04:00
2102546 RED+BLUE STRATEGIES 74fad7c9-b64b-40ff-bf1d-01f2005585b0 Q1 RED+BLUE STRATEGIES 400693064 PEW CHARITABLE TRUSTS 2018 first_quarter PHA H.R. 1625/PL 115-141 - Consolidated Appropriations Act of 2018 - Issues related to policies regarding antibiotic resistance, compounding, policies surrounding access to prescription medications and policies to combat the opioid crisis in the United States. H.R. 1301/PL 115-124 - Continuing Resolution of 2018 - Issues related access and affordability of prescription medications in the United States, treatment of biosimilars and generics in public and private insurance and policies to combat the opioid crisis in the United States. CMS regulations related to Medicare Part D and promulgation of laws related to curbing substance use disorder among Medicare beneficiaries. S. 1334/H.R. 2797 - Patient Choice and Quality Care Act of 2017 - Issues related to better integration of end-of-life and palliative care into the nation's health care system. H.R. 2871 - The Preserving Patient Access to Compounded Medications Act of 2017 - Concerns about how the bill could compromise safety protocols for compounded medications. Issues related to antibiotic innovation and advancement Issues related to monograph reform. Issues related to health information technology, unique device identifiers on Medicare claims forms, and other critical policies to promote device safety. Issues related to over the counter medications and supplements. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2018-04-06T15:25:52.453000-04:00
2103189 KATE MOSS d04d969c-bb1b-44e8-be64-787ad016430e Q1 KATE MOSS 25988 CVS HEALTH 2018 first_quarter PHA Legislation impacting PBMs and drug pricing HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2018-04-10T11:08:34.323000-04:00
2103310 INDEPENDENT PHARMACY COOPERATIVE 3bd7e7ac-d45f-4c97-962b-b74b827d5ea2 Q1 INDEPENDENT PHARMACY COOPERATIVE 313098 INDEPENDENT PHARMACY COOPERATIVE 2018 first_quarter PHA Medicare CONTRACT YEAR 2019 POLICY AND TECHNICAL CHANGES comments. Support drug price concessions at the point of sale and limiting excessive pharmacy credentialing requirements. Oppose proposed changes to LIS dual-eligible Special Enrollment Period (SEP). Support S. 109/H.R. 592, the Pharmacy and Medically Underserved Areas Enhancement Act Support S.413/H.R. 1038, the "Improving Transparency and Accuracy in Medicare Part D Drug Spending Act. Ensure patient choice in Comprehensive Addiction and Recovery Act of 2016 lock-in provision. Support S. 413 / H.R. 1038 the "Improving Transparency and Accuracy in Medicare Part D Drug Spending Act" Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE   30000 0 0 2018-04-10T13:38:22.923000-04:00
2103364 PENN AVENUE PARTNERS 86ef1dd4-c123-4efb-9eed-b7789cf3a157 Q1 PENN AVENUE PARTNERS 400918672 ALKERMES, INC. 2018 first_quarter PHA Regulatory and legislative issues impacting Alkermes. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2018-04-10T15:13:16.837000-04:00
2103368 PARRY, ROMANI, DECONCINI & SYMMS 013dc5ab-ff7b-4a42-8654-c0d3aa89cf2c Q1 PARRY, ROMANI, DECONCINI & SYMMS 30792 ROCK & ASSOCIATES 2018 first_quarter PHA Legislation affecting the operation of compounding pharmacies and the availability of compounded medications. H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017. HOUSE OF REPRESENTATIVES,SENATE 12000   0 0 2018-04-10T15:14:19.350000-04:00
2103988 ACG ADVOCACY c2226eb9-0a23-49e5-9d27-d06f0c962f76 Q1 ACG ADVOCACY 2057 WALGREEN CO. 2018 first_quarter PHA Competition Policy Issues. Drug Pricing Policy Issues. Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,SENATE 80000   0 0 2018-04-11T13:36:39.750000-04:00
2104567 AMERICAN SOCIETY FOR DERMATOLOGIC SURGERY ASSOCIATION 2668e6bb-c5d2-4ed9-8145-8d2de3915fac Q1 AMERICAN SOCIETY FOR DERMATOLOGIC SURGERY ASSOCIATION 401103437 AMERICAN SOCIETY FOR DERMATOLOGIC SURGERY ASSOCIATION 2018 first_quarter PHA FDA Regulatory Review Drug Shortage Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA)     0 0 2018-04-12T10:29:16.830000-04:00
2104734 AMERICAN CAPITOL GROUP d9970fd1-1d77-4e74-a278-7672390d491d Q1 AMERICAN CAPITOL GROUP 305852 CARDINAL HEALTH 2018 first_quarter PHA Issues Related to Distribution and Sale of Pharmaceutical and Medical Products and Services; Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 25000   0 0 2018-04-12T11:33:52.547000-04:00
2104861 ZHF CONSULTING LLC 8ad9f15f-8d8d-4890-8719-462c7f742768 Q1 ZHF CONSULTING LLC 401103689 MEDISCA, INC. 2018 first_quarter PHA Opioid crisis/alternative pain medication HOUSE OF REPRESENTATIVES,SENATE 22500   0 0 2018-04-12T12:40:23.653000-04:00
2104892 AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS 2c54eed7-2c49-44e2-9f4a-2885b9f1d21d Q1 AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS 3457 AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS 2018 first_quarter PHA Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, implementation of the Drug Quality and Security Act. Communication with Congress on compounding. Letter to Senate leadership regarding H.R. 1628, American Health Care Act of 2017. Testified to Senate on 340B Drug Discount Program. Communicated with House and Senate offices on drug shortages. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   200000 0 0 2018-04-12T12:54:34.977000-04:00
2104976 MR. VINCENT A. PANVINI b66ae863-ab16-430a-81ee-612f0b0c6de4 Q1 MR. VINCENT A. PANVINI 401008845 PHRMA 2018 first_quarter PHA Medicare Part D HOUSE OF REPRESENTATIVES,SENATE     0 0 2018-04-12T14:33:37.387000-04:00
2105006 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION eabbda3b-ed62-4229-9114-a5ccacc606e5 Q1 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 29403 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 2018 first_quarter PHA Pseudoephedrine Potential legislation to implement real-time, stop-sale electronic tracking system for sales of medications containing pseudoephedrine in order to preserve consumer access to the ingredient, common in popular cold and allergy medications (no bill number) and oppose prescription requirement (no bill number). Oral Contraceptives H.R. 421/S. 93 - Allowing Greater Access to Safe and Effective Contraception Act of 2017. Grants priority review of applications to switch oral contraceptive drugs from prescription to nonprescription (over-the-counter) status; all sections. Over-the-counter (OTC) medicines; Manufacturing and importation of OTC drugs; Mandatory recall authority of the FDA; Rx-to-OTC Switch Supporting a process within FDA that ensures clarity and timely outcomes for the FDA, applicants and stakeholders, as well as utilizing existing technologies to further streamline the prescription-to-nonprescription switch application process without changing the existing clear distinction between prescription and nonprescription medicines. Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE,Treasury, Dept of   192000 0 0 2018-04-12T14:54:52.687000-04:00
2105357 NATIONAL COMMUNITY PHARMACISTS ASSOCIATION 53162ac0-7c10-4d44-9488-274d36741fac Q1 NATIONAL COMMUNITY PHARMACISTS ASSOCIATION 27478 NATIONAL COMMUNITY PHARMACISTS ASSOCIATION 2018 first_quarter PHA Congressional Oversight of 340 B Program; Issues related to FDA implementation of The Drug Quality and Security Act related to the regulations of pharmacy compounding; Biosimilar naming; H.R. 421 Allowing Greater Access to Safe and Effective Contraception Act; H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017; HR 749, Lower Drug Costs through Competition Act Agriculture, Dept of (USDA),Centers For Medicare and Medicaid Services (CMS),Defense, Dept of (DOD),Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Government Accountability Office (GAO),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Medicare Payment Advisory Commission (MedPAC),Office of Management & Budget (OMB),Office of Natl Drug Control Policy (NDCP),Office of Personnel Management (OPM),SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA),White House Office   400000 0 0 2018-04-13T11:26:29.100000-04:00
2105858 THE D MAJOR GROUP ceb7e3ab-0c5b-46e1-aa61-9b49c5c61a2f Q1 THE D MAJOR GROUP 401103162 ALLERGAN INC (FORMERLY ACTAVIS INC ) 2018 first_quarter PHA Monitor issues concerning bioequivalence standards for pharmaceuticals. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2018-04-14T14:38:35.083000-04:00
2106345 MCDERMOTT+ LLC e4485d4b-2981-48f7-86d4-bc638a9223a7 Q1 MCDERMOTT+ LLC 401103287 ALLIANCE FOR RURAL HOSPITAL ACCESS 2018 first_quarter PHA Amendments to Section 340B of the Public Health Service Act to gain eligibility for rural referral centers and sole community hospitals in the federal discount drug purchasing program. Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2018-04-16T12:34:51.710000-04:00
2106868 CARD & ASSOCIATES, LLC 689aaf0b-4d75-4e49-b63c-754197bc0e0a Q1 CARD & ASSOCIATES, LLC 84217 AMAZON.COM (FRA PILLPACK AN AMAZON COMPANY) 2018 first_quarter PHA Educate Members on pharmacy contracting with pharmacy benefit managers H.R. 1316 Prescription Drug Price Transparency Act S. 637 Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act CMS-4182-P Technical Changes Defining Mail Order Pharmacy and Retail Pharmacy Comments-Final Regulations Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2018-04-16T16:35:58.037000-04:00
2107059 BROYDRICK & ASSOCIATES c83d2f76-2420-479c-bd92-38cc767933df Q1 BROYDRICK & ASSOCIATES 7268 TONIX PHARMACEUTICALS 2018 first_quarter PHA Funding for a new drug for PTSD. Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2018-04-16T18:06:12.847000-04:00
2107161 CONNECT 4 STRATEGIES, LLC 38635e5c-ae90-44c9-a67d-e24302eed149 Q1 CONNECT 4 STRATEGIES, LLC 401103720 OREXO US, INC. 2018 first_quarter PHA s916 Access to Emergency Medications Act Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2018-04-16T20:50:46.913000-04:00
2107297 PUBLIC CITIZEN d898d7b4-0d0f-447f-bc01-0843b3346b4e Q1 PUBLIC CITIZEN 32362 PUBLIC CITIZEN 2018 first_quarter PHA S. 771/HR 1776-Improving access to affordable Prescription Drugs act, S 2157-Drug Price transparency in Communications Act, S 2011/HR 4138-Medicare drug price negotiation act of 2017, S 1688-Empowering medicare seniors to negotiate drug prices of 2017, S 252-Medicare drug savings act of 2017, S 1369/HR 2974-Stop Price gouging act, S 124-Preserve access to affordable generics act, S 974/HR 2212-CREATES Act of 2017, S 495-Medical Innovation and Prize Fund Act, S 1131/HR 2439-FAIR drug pricing act, Over-the-counter Monograph Safety, Innovation, and Reform Act of 2018, HR 4117-Competitive DRUGS Act of 2017), HR 2051- FAST Generics Act of 2017), Prescription drug pricing, PACED Act, S 771/HR 1776 (Improving access to affordable prescription drugs act, S 1509/HR 1223 OPEN Act), S 1309-Stronger patents act, HR 5150 Protecting Medicare from excessive price increases act, S 2476-Expanding access to low cost generics act, S 637 (c-thru act), S 1348-SPIKE act, HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),Securities & Exchange Commission (SEC),SENATE,U.S. Trade Representative (USTR)   60000 0 0 2018-04-17T09:35:20.940000-04:00
2107420 COVINGTON & BURLING LLP 83e753de-59af-4a91-a45d-ab95aa306d8a Q1 COVINGTON & BURLING LLP 11195 FLEXION THERAPEUTICS, INC. 2018 first_quarter PHA Education and support for public policies that promote the development, use, coverage and reimbursement of novel, non-opioid pain therapies, including FDA Opioid Sparing legislation. HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2018-04-17T10:29:49.077000-04:00
2107542 CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER a68dbaa7-9a73-408e-81e6-497de617d7bb Q1 CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER 312496 CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER 2018 first_quarter PHA 340B drug pricing, PREA Agency for Healthcare Research & Quality (AHRQ),Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,White House Office   58456 0 0 2018-04-17T11:16:23.397000-04:00
2108372 HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA) 68d9e743-c290-4ed7-a3f9-62e6e53db9fe Q1 HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA) 28776 HEALTHCARE DISTRIBUTION ALLIANCE (FORMERLY - HDMA) 2018 first_quarter PHA Ensuring Patient Access and Effective Enforcement Act (Public Law 114-145); Prescription Drug Abuse - General issues related to Rx drug abuse; Importation of Prescription Drugs (S 469, S 771, HR 1776, HR 1245, HR 934, HR 1480, S 92, S 64), Implementation of Public Law 113-54 (DSCSA) Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   302335 0 0 2018-04-17T15:05:58.887000-04:00
2108394 LUNGREN LOPINA LLC ccb487a0-4224-4ad5-8c13-1ea6ce491aa7 Q1 LUNGREN LOPINA LLC 401103314 AMPAC FINE CHEMICALS 2018 first_quarter PHA Fair treatment for US pharmaceutical ingredients HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2018-04-17T15:10:18.903000-04:00
2108422 THE MATHIS HARPLE GROUP e76604a1-1b21-4838-b60f-081caaf75549 Q1 THE MATHIS HARPLE GROUP 322911 PILMA 2018 first_quarter PHA Medicare Part D HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2018-04-17T15:14:35.563000-04:00
2108445 BLUECROSS BLUESHIELD OF TENNESSEE 4a7f03ed-3c12-4dc8-91d0-be272e3772f9 Q1 BLUECROSS BLUESHIELD OF TENNESSEE 6440 BLUECROSS BLUESHIELD OF TENNESSEE 2018 first_quarter PHA General pharmacy and pharmaceutical issues; Opioid Abuse; prescription drug pricing; generic drug issues. Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   30000 0 0 2018-04-17T15:18:45.433000-04:00
2108558 ASSOCIATION OF NATIONAL ADVERTISERS, INC. 760ebf70-709a-44c4-b9d1-a08e154ed2c8 Q1 ASSOCIATION OF NATIONAL ADVERTISERS, INC. 4653 ASSOCIATION OF NATIONAL ADVERTISERS, INC. 2018 first_quarter PHA Proposals relating to the regulation of direct-to-consumer prescription drug advertising H.R. 4385, Responsibility in Drug Advertising Act of 2017, which would prohibit DTC advertising of prescription drugs for the first three years after FDA approval Federal Communications Commission (FCC),HOUSE OF REPRESENTATIVES,Natl Economic Council (NEC),SENATE,Treasury, Dept of   440000 0 0 2018-04-17T15:47:04.057000-04:00
2108634 MANATT, PHELPS, AND PHILLIPS 276a30c9-98fa-4338-92f7-0f2f7d63e5c0 Q1 MANATT, PHELPS, AND PHILLIPS 23645 NEKTAR THERAPEUTICS 2018 first_quarter PHA FDA oversight of certain pain reliever products Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 72000   0 0 2018-04-17T15:57:54.783000-04:00
2108642 ATRIUM HEALTH-FORMERLY KNOWN AS CAROLINAS HEALTHCARE SYSTEM 2132b6e2-b94a-4f78-a8dd-c59e8b350bf0 Q1 ATRIUM HEALTH-FORMERLY KNOWN AS CAROLINAS HEALTHCARE SYSTEM 58534 ATRIUM HEALTH - FORMERLY KNOWN AS CAROLINAS HEALTHCARE SYSTEM 2018 first_quarter PHA HR 4392 To provide that the provision of the Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs final regulation relating to changes in the payment amount for certain drugs and biologicals purchased under the 340B drug discount program shall have no force or effect, and for other purposes; HR 4710 340B PAUSE Act Any provision(s) reducing or changing the 340B Drug Discount Program or benefits to hospitals limiting hospital access to the benefit and or improving or updating the program's guidelines. HOUSE OF REPRESENTATIVES,SENATE   380270 0 0 2018-04-17T16:00:57.910000-04:00
2108733 KOUNTOUPES DENHAM CARR & REID, LLC 2623ab75-8876-47bb-9bc4-c531d20e789a Q1 KOUNTOUPES DENHAM CARR & REID, LLC 320918 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 2018 first_quarter PHA General issues related to over the counter pharmaceuticals. Issues related to draft legislation addressing the over the counter drug monograph process including H. R. 5333, the Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2018 and S. 2315, the Over-the-Counter Drug Safety, Innovation, and Reform Act. Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2018-04-17T16:23:11.467000-04:00
2108915 COVINGTON & BURLING LLP b6b5259c-d843-4485-9487-141b27c9ed75 Q1 COVINGTON & BURLING LLP 11195 CELGENE CORPORATION 2018 first_quarter PHA Expressing support for changes to the CREATES Act (H.R. 2212, S. 974) and Fair Access for Safe and Timely (FAST) Generics Act (H.R. 2051). HOUSE OF REPRESENTATIVES,SENATE 100000   0 0 2018-04-17T17:31:17.453000-04:00
2108931 BLUESTONE STRATEGIES, LLC e6f7f03d-90f5-442e-86de-f72606a8299f Q1 BLUESTONE STRATEGIES, LLC 400658980 AMERICA'S HEALTH INSURANCE PLANS (AHIP) 2018 first_quarter PHA Specialty Drugs and Prescription Drug Pricing HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2018-04-17T17:46:37.743000-04:00
2108941 BLUESTONE STRATEGIES, LLC f7797fd2-d59e-490b-a3eb-98a9f7cfc83c Q1 BLUESTONE STRATEGIES, LLC 400658980 PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA) 2018 first_quarter PHA Pharmacy Act; Drug Pricing; Generic Brand Settlement; Generic Dispensing; Generic Biologics; & Specialty Drug Issues. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2018-04-17T17:55:43.623000-04:00
2109059 THE METROHEALTH SYSTEM 0b45b472-043c-4d7f-b3c9-b69f88f945d7 Q1 THE METROHEALTH SYSTEM 288236 THE METROHEALTH SYSTEM 2018 first_quarter PHA 340B Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE   7500 0 0 2018-04-17T18:39:33.160000-04:00
2109147 MCDERMOTT WILL & SCHULTE LLP bb4759dc-0059-4389-8fd0-7c8e17741b90 Q1 MCDERMOTT WILL & SCHULTE LLP 24338 MAXOR NATIONAL PHARMACY SERVICES, LLC 2018 first_quarter PHA Efforts to monitor and address pharmacy and drug pricing-related legislative and regulatory proposals, including, but not limited to, the 340B Program. HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA) 40000   0 0 2018-04-17T19:32:41.017000-04:00
2109454 TAUZIN STRATEGIC NETWORKS 64b77f43-b1f1-490a-93b8-219aec4f9130 Q1 TAUZIN STRATEGIC NETWORKS 400786367 CAPTURERX 2018 first_quarter PHA Issues related to the 340b program HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2018-04-18T09:44:59.300000-04:00
2109577 MASS GENERAL BRIGHAM (FORMERLY KNOWN AS PARTNERS HEALTHCARE) ec365db3-71a3-4822-b2c5-2e27b6fb2ba5 Q1 MASS GENERAL BRIGHAM (FORMERLY KNOWN AS PARTNERS HEALTHCARE) 400265214 MASS GENERAL BRIGHAM (FORMERLY KNOWN AS PARTNERS HEALTHCARE) 2018 first_quarter PHA Pricing, shortages, and safety issues Centers For Medicare and Medicaid Services (CMS),Defense, Dept of (DOD),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE   122000 0 0 2018-04-18T10:13:15.947000-04:00
2110026 WINNING STRATEGIES WASHINGTON 64bb230d-b100-4ce8-9e83-e13296a82c9f Q1 WINNING STRATEGIES WASHINGTON 50796 KALEO 2018 first_quarter PHA Pharmaceutical drug development including epinephrine for anaphylaxis Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Natl Drug Control Policy (NDCP),SENATE 40000   0 0 2018-04-18T11:58:11.280000-04:00
2110040 WAXMAN STRATEGIES 6dd5d93c-1371-405f-bcab-7f220671edfa Q1 WAXMAN STRATEGIES 401103693 340B HEALTH 2018 first_quarter PHA Issues affecting the 340B drug pricing program; Pause Act HOUSE OF REPRESENTATIVES,SENATE 18750   0 0 2018-04-18T12:01:19.267000-04:00
2110055 WAXMAN STRATEGIES a2e06c8d-4f75-4c27-9712-966083f62c5e Q1 WAXMAN STRATEGIES 401103693 MEDICINES360 2018 first_quarter PHA Issues impacting the 340B drug discount program; Pause Act HOUSE OF REPRESENTATIVES     0 0 2018-04-18T12:05:28.270000-04:00
2110339 UC HEALTH 56f2d25e-e860-4b65-99ea-6ee99dc28ed3 Q1 UC HEALTH 401103195 UC HEALTH 2018 first_quarter PHA 340b program, drug pricing Centers For Medicare and Medicaid Services (CMS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE   10000 0 0 2018-04-18T13:01:12.030000-04:00
2110569 KOUNTOUPES DENHAM CARR & REID, LLC d19349c7-dc06-43ef-9668-3f91d162dd8c Q1 KOUNTOUPES DENHAM CARR & REID, LLC 320918 GLENMARK PHARMACEUTICALS, INC., USA 2018 first_quarter PHA General information about the company and the industry. Issues related to affordability and pricing of pharmaceuticals. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2018-04-18T13:41:01.537000-04:00
2110643 PRIME THERAPEUTICS bae21654-7898-47a2-8c66-36b16902af03 Q1 PRIME THERAPEUTICS 400339576 PRIME THERAPEUTICS 2018 first_quarter PHA S.778: Prescription Drug Monitoring Act--issues related to dispensers access to PDMP data across state lines. S.771/H.R.1776: Improving Access to Affordable Prescription Drugs Act--issues related to ensuring a competitive marketplace for prescription drugs. H.R.1939/S.1044: Ensuring Seniors Access to Local Pharmacies Act of 2017 (any willing pharmacy bill)--Provisions limiting payers' ability to selectively contract. S.2460/H.R.3528: Every Prescription Conveyed Securely Act--provisions requiring electronic prescribing of controlled substances in Medicare Part D (House Only). S.2554: "Patient Right to Know Drug Prices Act,"--provisions to prohibit the use of gag clauses or require that beneficiaries be charged lower prices. H.R.5343: "Prescription Transparency Act of 2018,"-- provisions to prohibit the use of gag clauses or require that beneficiaries be charged lower prices. HOUSE OF REPRESENTATIVES,SENATE   40000 0 0 2018-04-18T13:48:39.197000-04:00
2110672 NATIONAL ASSOCIATION OF CHAIN DRUG STORES 22e7d6aa-c985-46da-827f-2fba1a0bf105 Q1 NATIONAL ASSOCIATION OF CHAIN DRUG STORES 26672 NATIONAL ASSOCIATION OF CHAIN DRUG STORES 2018 first_quarter PHA H.R. 1245/S. 469 The Affordable and Safe Prescription Drug Importation Act H.R. 1316 - Prescription Drug Price Transparency Act H.R. 749 Lower Drug Costs Through Competition H.R.2430/S. 934 - FDA Reauthorization Act of 2017 H.R. 4841 - Standardizing Electronic Prior Authorization for Safe Prescribing Act Centers For Medicare and Medicaid Services (CMS),Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE   720000 0 0 2018-04-18T13:51:53.337000-04:00
2110737 FARRAGUT PARTNERS LLP 01c33024-c925-486e-8601-67a46ae53126 Q1 FARRAGUT PARTNERS LLP 401103938 AMERICAN SOCIETY OF INTERVENTIONAL PAIN PHYSICIANS 2018 first_quarter PHA Issues pertaining to Prescription Drug Monitoring programs. Public Health. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2018-04-18T14:04:41.500000-04:00
2110816 TARPLIN, DOWNS & YOUNG, LLC 031b59fd-6a49-4b0a-a7dd-1f5dbb3f808a Q1 TARPLIN, DOWNS & YOUNG, LLC 304736 BIOTECHNOLOGY INDUSTRY ORGANIZATION 2018 first_quarter PHA PL 114-255 - 21st Century Cures, implementation H.R. 2430 - FDA Reauthorization Act of 2017 ***, no specific bill(s), Drug Safety, Prescription Drug Importation, Import Safety, supply chain integrity, biosimilars, PDUFA and associated policies, patent settlements, accelerated approval, break through therapies, compounding, user fee reauthorization, Innovation Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE 80000   0 0 2018-04-18T14:18:23.100000-04:00
2110872 FARRAGUT PARTNERS LLP 3b296b8e-1bf7-4238-b9cf-ff82c1ebf9a7 Q1 FARRAGUT PARTNERS LLP 401103938 GENENTECH 2018 first_quarter PHA Prescription Drug User Fee Act reathorization. Oversight of 340B drug discount program. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2018-04-18T14:29:57.310000-04:00
2110885 PENN AVENUE PARTNERS 78b4ccbc-ffb5-4c8d-a8ed-ebe16ed3b5a2 Q1 PENN AVENUE PARTNERS 400918672 PURDUE PHARMA L.P. 2018 first_quarter PHA Monitoring legislative and regulatory activities impacting the pharmaceutical industry. SENATE 60000   0 0 2018-04-18T14:32:05.810000-04:00
2110901 FARRAGUT PARTNERS LLP 050a1d28-2a7a-4aaa-9c36-924989bcddf2 Q1 FARRAGUT PARTNERS LLP 401103938 BLUE CROSS BLUE SHIELD ASSOCIATION 2018 first_quarter PHA Laboratory developed tests 21st Century Cures HR 6 21st Century Cures Act Introduced May 19, 2015 by Fred Upton (RMI) This bill amends the Public Health Service Act to reauthorize the National Institutes of Health (NIH) through FY2018. The NIH Innovation Fund is established to fund a strategic plan, early stage investigators, and highrisk, highreward research. The NIH may require scientific data to be shared if the research is fully funded by the NIH. The NIH and the Food and Drug Administration (FDA) must implement a system that allows further research on clinical trial data. The Centers for Disease Control and Prevention must expand surveillance of neurological diseases. The Council for 21st Century Cures is established to accelerate the discovery, development, and delivery of innovative cures, treatments, and preventive measures. The Department of Health and Human Services must monitor the use of antibacterial and antifungal drugs and resistance to these drugs Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),Office of Management & Budget (OMB),SENATE,Treasury, Dept of,White House Office 50000   0 0 2018-04-18T14:35:17.500000-04:00
2110916 FARRAGUT PARTNERS LLP 2fcef8cf-71dd-4b1c-903d-9e097739f5c1 Q1 FARRAGUT PARTNERS LLP 401103938 COMMUNITY ONCOLOGY ALLIANCE 2018 first_quarter PHA Issues related to pharmacy benefit managers. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA) 80000   0 0 2018-04-18T14:38:28.907000-04:00
2110938 F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES 116e6d98-0aa0-4619-82f0-a54ae6f84062 Q1 F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES 18411 F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES 2018 first_quarter PHA S.1914 - Protecting Access to Diabetic Testing Supplies Act of 2017 Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   122279 0 0 2018-04-18T14:39:34.753000-04:00
2110975 TARPLIN, DOWNS & YOUNG, LLC 3efe7912-f425-485f-9add-a406a66c8296 Q1 TARPLIN, DOWNS & YOUNG, LLC 304736 HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) 2018 first_quarter PHA Importation of prescription drugs (S. 469, S. 771, H.R. 1776, H.R. 1245, H.R. 934, H.R. 1480, S. 92, S. 64) Opioid Drug Abuse - General issues related to opioid drug abuse Ensuring Patient Access and Effective Enforcement Act (PL 114-145) Implementation of Public Law 113-54 (DSCSA) Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 80000   0 0 2018-04-18T14:43:56.787000-04:00
2111008 FARRAGUT PARTNERS LLP 41c4311c-6caf-47ff-ad0f-c215d00845f9 Q1 FARRAGUT PARTNERS LLP 401103938 HERON THERAPEUTICS, INC. 2018 first_quarter PHA Issues related to opioid epidemic/specifically modifying rate setting for post surgical non opiods. HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2018-04-18T14:46:09.867000-04:00
2111082 MERCURY PUBLIC AFFAIRS, LLC 39dc9dee-5385-4d37-94aa-f6e35d5efd34 Q1 MERCURY PUBLIC AFFAIRS, LLC 70175 KALISPELL REGIONAL HEALTHCARE 2018 first_quarter PHA Veteran pharmacy issues and polices Federal Communications Commission (FCC),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA) 30000   0 0 2018-04-18T14:56:50.997000-04:00
2111233 MERCURY PUBLIC AFFAIRS, LLC ee2c16b4-4c7f-48fc-a073-83d61462cecf Q1 MERCURY PUBLIC AFFAIRS, LLC 70175 MORRIS AND DICKSON 2018 first_quarter PHA IT Help RE Improper Prescriptions Drug Enforcement Administration (DEA),Health & Human Services, Dept of (HHS) 20000   0 0 2018-04-18T15:26:25.573000-04:00
2111320 NOVO NORDISK INC. d2b3a93b-4ab7-41fc-83ff-761c5d32ad56 Q1 NOVO NORDISK INC. 284790 NOVO NORDISK INC. 2018 first_quarter PHA Issues related to P.L. 115-52 (H.R. 2430/S. 934) FDA Reauthorization Act of 2017 (Prescription Drug User Fee Act VI); H.R. 1245/S. 469 Affordable and Safe Prescription Drug Importation Act; H.R. 1776/S.771 Improving Access To Affordable Prescription Drugs Act; H.R. 4710, the 340B Protecting Access for the Underserved and Safety-Net Entities Act (340 PAUSE Act)and other issues related to 340B program Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Economic Council (NEC),SENATE,Veterans Affairs, Dept of (VA)   1460000 0 0 2018-04-18T15:33:23.187000-04:00
2111583 HANCE SCARBOROUGH 7d19af95-2caf-4171-8f77-ba1682a45f9d Q1 HANCE SCARBOROUGH 17443 ALLIANCE FOR PHARMACY COMPOUNDING 2018 first_quarter PHA Issues related to the regulation of pharmacy compounding. HR2871 Preserving Patient Access to Compounded Mediations Act. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2018-04-18T16:05:36.920000-04:00
2111603 PD FRAZER CONSULTING, INC. c0cd3b51-7678-4fa0-b43c-e51d24fe223c Q1 PD FRAZER CONSULTING, INC. 65998 CANADA INTERNATIONAL PHARMACY ASSOCIATION 2018 first_quarter PHA Support intent of H.R.1480 Safe and Affordable Drugs from Canada Act of 2017 Support intent of S.92 Safe and Affordable Drugs from Canada Act of 2017 Support intent of H.R. Affordable and Safe Prescription Drug Importation Act Support of S.469 Affordable and Safe Prescription Drug Importation Act HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2018-04-18T16:08:49.280000-04:00
2111654 AMERICAN VETERINARY MEDICAL ASSOCIATION 76ee0692-fcc4-4d55-92d8-e855177eeb10 Q1 AMERICAN VETERINARY MEDICAL ASSOCIATION 3630 AMERICAN VETERINARY MEDICAL ASSOCIATION 2018 first_quarter PHA H.R. 623, Fairness to Pet Owners Act; S.2434 Animal Drug and Animal Generic Drug User Fee Amendments of 2018 Anticipated legislative package related to the opioid crisis, principles of opioid use in veterinary medicine Docket No. FDA-2017-n-6502: Citation 82 FR 5872: Opioid Policy Steering Committee: Prescribing Intervention - Exploring a Strategy for Implementation: Public Hearing: Request for Comments Animal Drug and Animal Generic Drug User Fee Reauthorization Agriculture, Dept of (USDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Internal Revenue Service (IRS),Labor, Dept of (DOL),SENATE,Treasury, Dept of   200000 0 0 2018-04-18T16:13:08.190000-04:00
2111711 HANCE SCARBOROUGH 776f96f7-e6a2-4b44-bbcb-e0444efe0063 Q1 HANCE SCARBOROUGH 17443 TITAN PHARMACEUTICALS, INC. 2018 first_quarter PHA Medicare/Medicaid drug coverage,opioid addiction policy, S.2456 The CARA 2.0 Act of 2018. HOUSE OF REPRESENTATIVES,SENATE     0 0 2018-04-18T16:18:37.537000-04:00
2112392 FTI GOVERNMENT AFFAIRS 40b124e8-2539-4540-bbb8-5211ceda66b0 Q1 FTI GOVERNMENT AFFAIRS 401054971 PERRIGO, INC. 2018 first_quarter PHA Repeals a requirement enacted into law as part of the PPACA of 2010 that requires consumers to obtain a prescription in order to utilize their FSA's and HSA's to purchase over-the-counter OTC medicines. FDA's proposed changes to generic drug labeling. House Energy and Commerce 21st Century Cures Initiative. Senate Health, Education, Labor and Pensions 21st Century Cures Initiative. "Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2018", H.R. 5333. "Over-the-Counter Drug Safety, Innovation, and Reform Act", S. 2315. HOUSE OF REPRESENTATIVES,SENATE 150000   0 0 2018-04-18T19:40:26.347000-04:00
2112399 FTI GOVERNMENT AFFAIRS a4f00c6c-cf66-4c07-a1f4-234a323d4bd9 Q1 FTI GOVERNMENT AFFAIRS 401054971 PROFESSIONAL COMPOUNDING CENTERS OF AMERICA 2018 first_quarter PHA Implementation of The Drug Quality and Security Act, H.R.3204 (Public Law) ((USP/NF Monograph)). Monitor H.R.2871 "Preserving Patient Access to Compounded Medication Act of 2017. " HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2018-04-18T19:48:31.553000-04:00
2112472 DAIICHI SANKYO, INC. 97262875-0914-43b8-a421-34c7bdc7392b Q1 DAIICHI SANKYO, INC. 316731 DAIICHI SANKYO INC 2018 first_quarter PHA Discussions regarding opioid abuse Discussions regarding 340B drug discount program S.974,Creating and Restoring Equal Access To Equivalent Samples Act of 2017 (CREATES Act of 2017) Discussions regarding PBM patient assistance limitations     130000 0 0 2018-04-18T22:33:09.697000-04:00
2112485 ARENTFOX SCHIFF LLP 5ecd9341-5e3b-40d7-89bd-c61fc10c2e40 Q1 ARENTFOX SCHIFF LLP 4208 KEMPHARM, INC. 2018 first_quarter PHA FDA regulation of opioid abuse deterrent formulations HOUSE OF REPRESENTATIVES,SENATE,White House Office 30000   0 0 2018-04-18T23:38:18.590000-04:00
2112528 VAN SCOYOC ASSOCIATES 3c2189b9-c4f0-42eb-9b81-cfdbe277f460 Q1 VAN SCOYOC ASSOCIATES 39837 ZEBRA TECHNOLOGIES CORP. 2018 first_quarter PHA Public Law 113-54, Drug Quality and Security Act, Drug labeling implementation HOUSE OF REPRESENTATIVES 10000   0 0 2018-04-19T04:09:55.897000-04:00
2112791 IMPACT HEALTH POLICY PARTNERS f47c2ad9-00d3-4c83-ba75-bce6e2be394e Q1 IMPACT HEALTH POLICY PARTNERS 401104696 EXPRESS SCRIPTS 2018 first_quarter PHA Pharmacy benefits manager standards under the Medicare prescription drug program to further transparency of payment methodologies to pharmacies. Issues related to a pilot program in TRICARE that would establish Department of Defense (DoD) acquisition cost parity for prescription drugs obtained at community pharmacies. Drug reimbursement and general pharmacy related issues. S.637, Creating Transparency to Have Drug Rebates Unlocked (CTHRU) Act of 2017; issues related to transparency of pharmacy benefit managers (PBMs). Centers For Medicare and Medicaid Services (CMS) 30000   0 0 2018-04-19T07:04:16.873000-04:00
2112969 APOTEX CORP. 3db1af50-046d-455b-9105-d95df1410986 Q1 APOTEX CORP. 310973 APOTEX CORP. 2018 first_quarter PHA Federal policy related to Section 603, Applying the Medicaid additional rebate requirement to generics, of Public Law No 114-67, the Bipartisan Budget Act of 2015; and S. 2476, the Expanding Access to Low Cost Generics Act, provisions relating to pharmaceutical market blockages caused by "parked" Hatch-Waxman 180 day exclusivity periods. HOUSE OF REPRESENTATIVES,SENATE   160000 0 0 2018-04-19T09:24:22.117000-04:00
2113205 APOTEX CORP. 12c320df-fa90-4c25-8320-8363bacf0561 1A APOTEX CORP. 310973 APOTEX CORP. 2018 first_quarter PHA Federal policy related to Section 603, Applying the Medicaid additional rebate requirement to generics, of Public Law No 114-67, the Bipartisan Budget Act of 2015; and S. 2476, the Expanding Access to Low Cost Generics Act, provisions relating to pharmaceutical market blockages caused by "parked" Hatch-Waxman 180 day exclusivity periods. HOUSE OF REPRESENTATIVES,SENATE   500000 0 0 2018-04-19T09:59:22.727000-04:00
2113242 MERCY HEALTH SYSTEM 0538dc67-60e7-4708-858b-9e88351c4c7d Q1 MERCY HEALTH SYSTEM 40043344 MERCY HEALTH SYSTEM 2018 first_quarter PHA Palliative Care 340 B Drug program Health Care Reform HOUSE OF REPRESENTATIVES,SENATE   8000 0 0 2018-04-19T10:04:54.337000-04:00
2113501 BROWN RUDNICK LLP 9d3cbd2f-ac68-4711-8062-f50aa98e2072 Q1 BROWN RUDNICK LLP 287895 HEALTHCARE DISTRIBUTION ALLIANCE F/K/A HEALTHCARE DISTRIBUTION MANAGEMENT ASSOC 2018 first_quarter PHA Public Law 113-54-Drug Quality and Security Act; S.469-The Affordable and Safe Prescription Drug Importation Act; H.R. 5267 relating to DEA controlled substances registration; Public Law 114-145-The Ensuring Patient Access and Effective Drug Enforcement Act; Issues relating to prescription drug abuse and diversion. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2018-04-19T10:29:00.680000-04:00
2113507 ALKERMES, INC. 18b30f15-b710-4196-baf3-b63740376faf Q1 ALKERMES, INC. 400458235 ALKERMES, INC. 2018 first_quarter PHA Public law #114-198, 21st Century Cures Opioid Implementation Awareness of outcomes data and the need for training on all medication assisted treatment Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Natl Institutes of Health (NIH),Office of Natl Drug Control Policy (NDCP),SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA),Veterans Affairs, Dept of (VA)   1000000 0 0 2018-04-19T10:29:04.680000-04:00
2113648 MWW GROUP 453df78e-3ee0-4509-b8cd-0ed18dd163cd Q1 MWW GROUP 26318 UNITED PHARMACY PARTNERS, INC. (UPPI) 2018 first_quarter PHA Draft legislation regarding High Enriched Uranium (HEU) HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2018-04-19T10:43:31.907000-04:00
2113703 ELI LILLY AND COMPANY 2c463684-dc8c-4730-bf3f-08dfc814ed27 Q1 ELI LILLY AND COMPANY 13392 ELI LILLY AND COMPANY 2018 first_quarter PHA Hospital discounts; 340B program Agriculture, Dept of (USDA),Commerce, Dept of (DOC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Natl Institutes of Health (NIH),Office of Management & Budget (OMB),SENATE,State, Dept of (DOS),U.S. Trade Representative (USTR)   1340000 0 0 2018-04-19T10:49:11-04:00
2113757 MASSACHUSETTS MEDICAL SOCIETY 8843ac1a-4cac-4224-ab89-61266a364a40 Q1 MASSACHUSETTS MEDICAL SOCIETY 23975 MASSACHUSETTS MEDICAL SOCIETY 2018 first_quarter PHA S. 771 - Improving Access to Affordable Prescription Drugs - Legislation that seeks to address prescription drug costs by increasing transparency and accountability, boosting access and affordability of key drugs, spurring innovation, and increasing choice and competition by allowing Medicare to negotiate the price of drugs, among other provisions. Efforts to require the manufacturers suggested retail price of prescription drugs in direct to consumer advertising of prescription drugs - no specific bill Centers For Medicare and Medicaid Services (CMS),Drug Enforcement Administration (DEA),HOUSE OF REPRESENTATIVES,SENATE   100000 0 0 2018-04-19T10:51:30.440000-04:00
2114026 ISEMAN & ASSOCIATES LLC d6287129-43e8-47dc-a1e4-3dc1a30e4177 Q1 ISEMAN & ASSOCIATES LLC 401103582 TICHENOR VENTURES, LLC 2018 first_quarter PHA Monitoring biotech legislation HOUSE OF REPRESENTATIVES,SENATE 12500   0 0 2018-04-19T11:13:17.937000-04:00
2114358 FLYNN & ASSOCIATES, INC. c82310df-0d3b-4cf6-98fc-315fbb3fb367 Q1 FLYNN & ASSOCIATES, INC. 15020 PHARMACEUTICAL INDUSTRY LABOR-MANAGEMENT ASSOCIATION 2018 first_quarter PHA Childrens Health Insurance Program Importation of drugs from Canada HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2018-04-19T11:49:31.767000-04:00
2114453 NELSON MULLINS RILEY & SCARBOROUGH a5c98d06-760b-4e0c-a5c3-99b38d925d8e Q1 NELSON MULLINS RILEY & SCARBOROUGH 285871 CASCADE HEMOPHILIA CONSORTIUM 2018 first_quarter PHA Issues related to 340B Drug Pricing Program HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2018-04-19T11:59:29.490000-04:00
2114469 NELSON MULLINS RILEY & SCARBOROUGH 26daff48-2929-4955-958c-2e9ec55cebf5 Q1 NELSON MULLINS RILEY & SCARBOROUGH 285871 HEMOPHILIA OF GEORGIA 2018 first_quarter PHA Issues related to the 340B Drug Pricing Program and biomedical research HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2018-04-19T12:01:40.757000-04:00
2114488 NATIONAL HOME INFUSION ASSOCIATION 4cf26742-ef0a-452e-8c3b-96637af35170 Q1 NATIONAL HOME INFUSION ASSOCIATION 40047365 NATIONAL HOME INFUSION ASSOCIATION 2018 first_quarter PHA Compounding pharmacy regulation - worked to ensure DQSA (Pub L. 113-54) is being properly implemented, specifically the draft memorandum of understanding for 503 A pharmacies and FDA inspections of 503A pharmacies. Lobbied for the inclusion of Department of Agriculture/FDA appropriations language regarding inspection authority and scope of the draft memorandum of understanding Lobbied on proper inspections of 503A pharmacies Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   130000 0 0 2018-04-19T12:02:53.180000-04:00
2114619 ATRIUM HEALTH-FORMERLY KNOWN AS CAROLINAS HEALTHCARE SYSTEM 637ac843-556d-42ce-be02-f5916c019d9f Q1 ATRIUM HEALTH-FORMERLY KNOWN AS CAROLINAS HEALTHCARE SYSTEM 58534 ATRIUM HEALTH - FORMERLY KNOWN AS CAROLINAS HEALTHCARE SYSTEM 2018 first_quarter PHA HR 4392 To provide that the provision of the Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs final regulation relating to changes in the payment amount for certain drugs and biologicals purchased under the 340B drug discount program shall have no force or effect, and for other purposes; HR 4710 340B PAUSE Act Any provision(s) reducing or changing the 340B Drug Discount Program or benefits to hospitals limiting hospital access to the benefit and or improving or updating the program's guidelines. HOUSE OF REPRESENTATIVES,SENATE   380270 0 0 2018-04-19T12:16:24.917000-04:00
2114655 ISEMAN & ASSOCIATES LLC 1987260a-fb09-482b-9028-9c68200d085d Q1 ISEMAN & ASSOCIATES LLC 401103582 TICHENOR VENTURES, LLC 2018 first_quarter PHA Monitoring biotech legislation HOUSE OF REPRESENTATIVES,SENATE 12500   0 0 2018-04-19T12:19:28.500000-04:00
2114700 OREGON HEALTH & SCIENCE UNIVERSITY a6551ea0-2e1f-4d3a-bfa5-6f51d50687d0 Q1 OREGON HEALTH & SCIENCE UNIVERSITY 30291 OREGON HEALTH & SCIENCE UNIVERSITY 2018 first_quarter PHA 340b Drug Discount Program for safety net hospitals and Health Resources and Services Administration proposed omnibus guidance. HOUSE OF REPRESENTATIVES,SENATE   80000 0 0 2018-04-19T12:21:54.267000-04:00
2114966 KNIGHT CAPITOL CONSULTANTS b09ab41e-e510-43ae-80e8-36b56705c449 Q1 KNIGHT CAPITOL CONSULTANTS 40036301 EQUASHIELD, LLC 2018 first_quarter PHA Monitor issues related to Medical Device User Fee Act reauthorization contained in the Food and Drug Administration Reauthorization Act (PL 115-52) Centers For Disease Control & Prevention (CDC),SENATE 30000   0 0 2018-04-19T12:50:18.627000-04:00
2115295 KOUNTOUPES DENHAM CARR & REID, LLC dcf75b6b-4642-4222-ac69-c52ad0fa1fc4 Q1 KOUNTOUPES DENHAM CARR & REID, LLC 320918 CVS HEALTH 2018 first_quarter PHA General education about the pharmacy benefit manager/pharmacy industry, including S.637, The Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act. Issues related to Risk Evaluation and Mitigation Strategies (REMS) program, including S.974 and H. R. 2212, The CREATES Act. Proactive measures to curb opioid abuse. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),Office of the Vice President of the United States,SENATE,White House Office 50000   0 0 2018-04-19T13:26:58.440000-04:00
2115305 FORBES-TATE c0be814f-c147-48cf-9b05-61b925f0adc5 Q1 FORBES-TATE 400976792 PHRMA 2018 first_quarter PHA Issues pertaining to Rx Drug pricing. HOUSE OF REPRESENTATIVES,SENATE 80000   0 0 2018-04-19T13:28:05.973000-04:00
2115345 KNIGHT CAPITOL CONSULTANTS 47b6864e-795b-4d03-8db5-72e3c724bbc2 Q1 KNIGHT CAPITOL CONSULTANTS 40036301 INDIVIOR, INC. 2018 first_quarter PHA H.R. 5202/S. 916 Section 3: Ensuring Patient Access to Substance Use Disorder Treatments Act of 2018 HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2018-04-19T13:31:29.850000-04:00
2115467 AKIN GUMP STRAUSS HAUER & FELD 4460ed7d-96c6-45c2-a41f-7234c48e4e7b Q1 AKIN GUMP STRAUSS HAUER & FELD 682 PHARMEDIUM SERVICES, LLC 2018 first_quarter PHA Drug Quality and Security Act, Pub. L. 113-54; FDA regulatory implementation of Section 503B of the Food, Drug and Cosmetic Act; FDA Pharmacy Compounding Advisory Committee; House & Senate Agriculture, FDA & Related Agency Appropriations bills; H.R. 2871, Preserving Patient Access to Compounded Medications Act of 2017. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 100000   0 0 2018-04-19T13:44:51.247000-04:00
2115636 TARPLIN, DOWNS & YOUNG, LLC fa50cbaa-54d1-4c19-9e81-e6e0b1459553 Q1 TARPLIN, DOWNS & YOUNG, LLC 304736 PHRMA 2018 first_quarter PHA PL 114-255 - 21st Century Cures, implementation ***, no specific bill(s), prescription drug importation, import safety, supply chain integrity, Prescription Drug User Fee Act Fee Reauthorization and associated policies, user fee sequester, innovation Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 80000   0 0 2018-04-19T13:56:36.567000-04:00
2115804 AMERICAN PHARMACISTS ASSOCIATION b8fd7bb0-c886-4055-bb13-679735c9c5b3 Q1 AMERICAN PHARMACISTS ASSOCIATION 3071 AMERICAN PHARMACISTS ASSOCIATION 2018 first_quarter PHA HR 1038, S 413 Improving Transparency and Accuracy in Medicare Part D Spending Act HR 1939 To amend title XVIII of the Social Security Act to ensure equal access of Medicare beneficiaries to community pharmacies in underserved areas as network pharmacies under Medicare prescription drug coverage, and for other purposes. HR 592, S 109 To amend title XVIII of the Social Security Act to provide for coverage under the Medicare program of pharmacist services. HR 1480 Safe and Affordable Drugs from Canada Act of 2017 S 637 Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017 HR 1586 To amend the Federal Food, Drug, and Cosmetic Act to ensure that liquid over-the-counter medications are packaged with appropriate dosage delivery devices and, in the case of such medications labeled for pediatric use, appropriate flow restrictors, and for other purposes. S 778 Prescription Drug Monitoring Act of 2017 HR 934 Personal Drug Importation Fairness Act of 2017 HR 421 Allowing Greater Access to Safe and Effective Contraception Act S 1079 Protecting Americans from Dangerous Opioids Act HR 2567 Access to Birth Control Act HR 2871 Preserving Patient Access to Compounded Medications Act of 2017 HR 2063 Opioid PACE Act of 2017 S 1003 A bill to amend title XIX of the Social Security Act to add standards for drug compendia for physician use for purposes of Medicaid payment for certain drugs, and for other purposes HR 1939/S 1044 Ensuring Seniors Access to Local Pharmacies Act of 2017 S 469 Affordable and Safe Prescription Drug Importation Act HR 3727 To amend title XVIII of the Social Security Act to include additional telehealth services for purposes of MA organization bids, and for other purposes. HR 2430 FDA Reauthorization Act of 2017 HR 3528/S 2460 Every Prescription Conveyed Securely Act HOUSE OF REPRESENTATIVES,SENATE   34000 0 0 2018-04-19T14:10:30.073000-04:00
2116531 340B HEALTH 1809a348-8fdf-41ba-9abd-ff00943b8611 Q1 340B HEALTH 316434 340B HEALTH 2018 first_quarter PHA The 340B Drug Pricing Program, FY18 LHHS Appropriations, FY19 LHHS Appropriations, final 2018 Outpatient Prospective Payment System Rule, proposed and final rules regarding 340B ceiling price calculations and manufacturer civil monetary penalties, S.2312, S.2453, H.R.4710, H.R.4392 Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE   269487 0 0 2018-04-19T14:54:56.703000-04:00
2117291 LEHIGH VALLEY HEALTH NETWORK 1c0e0f59-b9ab-4bfe-809b-5ef91d807149 Q1 LEHIGH VALLEY HEALTH NETWORK 40041332 LEHIGH VALLEY HEALTH NETWORK 2018 first_quarter PHA Supporting the continuation of 340B program Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE   20000 0 0 2018-04-19T15:38:32.553000-04:00
2117461 UNITE HERE! 53d187d9-0dc4-420f-9e7e-36cefd00436e Q1 UNITE HERE! 38984 UNITE HERE! 2018 first_quarter PHA Advocating for the passage of: H.R. 1245-Affordable and Safe Prescription Drug Importation Act S. 469-Affordable and Safe Prescription Drug Importation Act H.R. 1776-Improving Access to Affordable Prescription Drugs Act Opposing the Nomination of Mr. Alex Azar to Secretary of HHS AMTRAK - Natl Railroad Passenger Corporation,Federal Trade Commission (FTC),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Internal Revenue Service (IRS),Justice, Dept of (DOJ),Labor, Dept of (DOL),Natl Mediation Board,Pension Benefit Guaranty Corporation (PBGC),SENATE,State, Dept of (DOS) 88758   0 0 2018-04-19T15:48:30.340000-04:00
2117640 MEHLMAN CONSULTING, INC. 0ac5e204-99ab-41f8-80f3-96814ee3d0bc Q1 MEHLMAN CONSULTING, INC. 284950 VIRTUS PHARMACEUTICALS LLC 2018 first_quarter PHA FDA Drug Approval HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2018-04-19T16:00:27.487000-04:00

Next page

Advanced export

JSON shape: default, array, newline-delimited, object

CSV options:

CREATE TABLE lobbying_activities (
            id INTEGER PRIMARY KEY,
            filing_uuid TEXT NOT NULL,
            filing_type TEXT NOT NULL,
            registrant_name TEXT NOT NULL,
            registrant_id INTEGER,
            client_name TEXT NOT NULL,
            filing_year INTEGER NOT NULL,
            filing_period TEXT NOT NULL,
            issue_code TEXT,
            specific_issues TEXT,
            government_entities TEXT,
            income_amount INTEGER,
            expense_amount INTEGER,
            is_no_activity INTEGER DEFAULT 0,
            is_termination INTEGER DEFAULT 0,
            received_date TEXT,
            CONSTRAINT fk_activity_filing FOREIGN KEY (filing_uuid)
                REFERENCES lobbying_filings_raw(filing_uuid)
        );
CREATE INDEX idx_act_client_name ON lobbying_activities(client_name COLLATE NOCASE);
CREATE INDEX idx_act_issue_code ON lobbying_activities(issue_code);
CREATE INDEX idx_act_filing_year ON lobbying_activities(filing_year);
CREATE INDEX idx_act_filing_uuid ON lobbying_activities(filing_uuid);
Powered by Datasette · Queries took 3383.259ms · Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API